- Home
- SANA vs GPCR Comparison
SANA vs GPCR Comparison
Compare SANA & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SANA | GPCR |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SANA | GPCR |
|---|---|---|
| Price | $4.45 | $68.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $7.83 | ★ $97.90 |
| AVG Volume (30 Days) | ★ 4.0M | 1.3M |
| Earning Date | 11-06-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $13.22 |
| 52 Week High | $7.30 | $94.90 |
Technical Indicators
Market Signals| Indicator | SANA | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 62.16 |
| Support Level | $4.01 | $61.99 |
| Resistance Level | $4.91 | $70.40 |
| Average True Range (ATR) | 0.27 | 3.98 |
| MACD | -0.00 | -1.19 |
| Stochastic Oscillator | 52.04 | 58.29 |
Price Performance
Historical ComparisonAbout SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.